教育背景
2011-2015 吉林大学药学院 学士
2015-2018 北京大学基础医学院 硕士
2018-2023 瑞士洛桑联邦理工学院 博士
工作经历
2023-2026 斯坦福大学 博士后
2023-2026 癌症研究所（CRI） 博士后
2026-至今 清华大学基础医学院 助理教授
研究领域
赵扬博士的研究领域为抗肿瘤合成免疫治疗策略的开发，主要关注于通过工程化生物分子与合成信号元件构建可编程免疫系统，以提升T细胞在复杂肿瘤微环境中的功能适应性、信号整合能力与持续抗肿瘤效应。主要研究方向包括工程化细胞因子设计与优化、免疫受体文库的构建与功能筛选，以及工程化T细胞治疗体系的开发与功能优化等，旨在建立可模块化设计、可精确调控的免疫工程平台，用于提升肿瘤免疫治疗的可编程性与功能可塑性。
科学贡献
赵扬博士在合成免疫治疗与T细胞功能重编程领域开展了系统性研究，围绕工程化细胞因子、受体信号重构及合成蛋白平台，深入解析并调控T细胞关键功能状态及其底层信号网络，在代谢调控、信号通路重编程及细胞命运塑造等方面取得系列进展。主要科学贡献包括：（1）揭示IL-10可驱动CAR-T细胞代谢程序重塑，从而显著增强其在实体瘤微环境中的存活能力与持续抗肿瘤效应（Nature Biotechnology 2024）。（2）发现γ链可与非天然受体形成新的功能性配对关系，系统性拓展JAK/STAT信号激活谱系，实现T细胞功能状态与谱系的定向重编程，并在实体瘤模型中展现出显著增强的治疗效果（Nature 2025）。（3）构建基于工程化细胞因子的合成信号平台，实现非天然STAT信号的可控与可编程激活，为T细胞功能增强与信号设计提供新的模块化分子框架（Science 2026）。（4）开发免疫靶点成像与动态监测技术体系，用于免疫反应的实时评估与治疗响应预测（PNAS 2021; Cancer Research 2017）。
代表性论文
(#Co-first author; *Corresponding author)
1. Zhao Y, Ogishi M, Pal A, Su LL, Jiang H, Tao P, Rodriguez GE, Sun Q, Rysavy LW, Limsuwannarot S, Waghray D, Kalbasi A*, Garcia KC*. Expanding the cytokine receptor alphabet in T cells generates diverse cell states. Nature, 2025, 645, pages 1039–1050 (2025).
2. Rodriguez GE#, Zhao Y#, Abhiraman GC, Ogishi M, Zhang C, Saco J, Torres L, Simone BW, Waghray D, Su L, Wilson S, Yang A, Sun Q, Obenaus M, Picton L, Saxton RA, Bhandarkar V, Andrews E, Jiang H, Yen M, Atajanova T, Dougan M, Spranger S, Wherry EJ, Ribas A, Raulet DH, Kalbasi A, Garcia KC*. Rewiring STAT signaling from the cell surface with Trikines enhances immunotherapy. Science, 2026, May 14;392(6799).
3. Broerman A, Pollmann C, Zhao Y, Lichtenstein MA, Jackson MD, Tessmer MH, Ryu WH, Ogishi M, Abedi MH, Sahtoe DD, Allen A, Kang A, Cruz JDL, Brackenbrough E, Sankaran B, Bera AK, Zuckerman DM, Stoll S, Garcia KC, Praetorius F*, Piehler J*, Baker D*. Design of Induced Acceleration of Protein Complex Dissociation. Nature. 2025, 647, pages 528–535.
4. Householder KD, Xiang X, Jude KM, Deng A, Obenaus M, Zhao Y, Wilson SC, Chen X, Wang N, Garcia KC*. De novo design and structure of a peptide-centric TCR mimic binding module. Science, 2025 July; 389 (6758): 375-379.
5. Sun Q, Lyu H, Ogishi M, Jiang H, Zhao Y, Liu H, Rodriguez GE, Tao P, Obenaus M, Householder KD, Tang Q, Garcia KC*. Facile Induction of Peripheral Immune Tolerance by an IL-2-TGF-β Surrogate Agonist. Nature, 653, pages888–899 (2026)
6. Zhao Y#, Chen J#, Andreatta M, Feng B, Xie YQ, Wenes M, Wang Y, Gao M, Hu X, Romero P, Carmona S, Sun J*, Guo Y*, Tang L*. IL-10-expressing CAR T cells resist dysfunction and mediate durable clearance of solid tumors and metastases. Nature Biotechnology 2024, Jan; 42, 1693–1704. (Cover story)
7. Feng B#, Bai Z#, Zhou X, Zhao Y, Xie YQ, Huang X, Wang Y, Li R, Gao M, Bonati L, Charmoy M, Held W, Fan R*, Guo Y*, Tang L*. A type 2 cytokine Fc–IL-4 reinvigorates terminally exhausted CD8+ T cells to potentiate anticancer immunotherapy. Nature. 2024 Sept; 634, 712–720.
8. Zhao Y*. Cytokines 2025: 13th Annual Meeting of the International Cytokine and Interferon Society. Journal of Interferon & Cytokine Research, 2026 Jul;46(7):185-188.
9. Wang Y, Huang C, Cai G, Andreatta M, Kurum A, Zhao Y, Feng B, Gao M, Carmona S, Zhou Z, Sun C, Guo Y, Tang L*. Metabolic reinvigoration of NK cells by IL-21 enhances immunotherapy against MHC-I deficient solid tumors. Cell report. 2026; 45.
10. Guo Y#, Xie YQ#, Gao M, Zhao Y, Franco F, Wenes M, Siddiqui I, Bevilacqua A, Wang H, Yang H, Feng B, Xie X, Sabatel CM, Tschumi B, Chaiboonchoe A, Wang Y, Li W, Xiao W, Held W, Romero P, Ho PC*, Tang L*. Metabolic reprogramming of terminally exhausted CD8+ T cells by IL-10 enhances antitumor immunity. Nature Immunology. 2021 Jun; 22, 746–756.
11. Zhao Y#, Zhang T#, Wang Y, Lu D, Du J, Feng X, Zhou H, Liu N, Zhu H, Qin S, Liu C, Gao X, Yang Z, Liu Z*. ICAM-1 orchestrates the abscopal effect of tumor radiotherapy. PNAS. 2021 Apr 6;118(14):e2010333118.
12. Zhang T#, Zhang Y#, Zhao Y, Song R, Wang Y, Li K, Zhou H, Wang F, Zhou S, Zhu H, Yang Z, Liu Z*. Annotation of CD8+ T-cell function via ICAM-1 imaging identifies FAK inhibition as an adjuvant to augment the antitumor immunity of radiotherapy. Theranostics. 2024 Jan 1;14(2):699-713.
13. Wang Y, Zhang C, Lai J, Zhao Y, Lu D, Bao R, Feng X, Ting Z, Liu Z*. Noninvasive PET tracking of post-transplant gut microbiota in living mice. Eur J Nucl Med Mol Imaging. 2020 Apr;47(4):991-1002.
14. Bao R, Wang Y, Lai J, Zhu H, Zhao Y, Li N, Huang J, Yang Z, Wang F, Liu Z*. Enhancing Anti-PD-1/PD-L1 Immune Checkpoint Inhibitory Cancer Therapy by CD276-Targeted Photodynamic Ablation of Tumor Cells and Tumor Vasculature. Mol Pharm. 2019 Jan;16(1):339-348.
15. Lai J, Lu D, Zhang C, Zhu H, Gao L, Wang Y, Bao R, Zhao Y, Jia B, Wang F, Yang Z, Liu Z*. Noninvasive small-animal imaging of galectin-1 upregulation for predicting tumor resistance to radiotherapy. Biomaterials. 2018 Mar; 158:1-9.
16. Zhao Y, Zhang C, Gao L, Yu X, Lai J, Lu D, Bao R, Wang Y, Jia B, Wang F, Liu Z*. Chemotherapy-induced macrophage infiltration into tumors enhances nanographene-based photodynamic therapy. Cancer Res. 2017 Nov;77(21):6021-6032.
17. Yu X, Gao D, Gao L, Lai J, Zhang C, Zhao Y, Zhong L, Jia B, Wang F, Chen X, Liu Z*. Inhibiting Metastasis and Preventing Tumor Relapse by Triggering Host Immunity with Tumor-Targeted Photodynamic Therapy Using Photosensitizer-Loaded Functional Nanographenes. ACS Nano. 2017 Oct;11(10):10147-10158.
18. Zhang C, Yu X, Gao L, Zhao Y, Lai J, Lu D, Bao R, Jia B, Zhong L, Wang F, Liu Z*. Noninvasive imaging of CD206-positive M2 macrophages as an early biomarker for post-chemotherapy tumor relapse and lymph node metastasis. Theranostics. 2017 Sep 26;7(17):4276-4288.
专利
• Zhao Y, Tang L, Guo Y. “IL-10-expressing cells for enhanced cancer immunotherapies”. No. PCT/EP2022/073462, 2022
• Zhao Y, Tang L, Enbar T, Feng B. “Engineered type 2 cytokine signalling to improve CAR-T cell effector functions”. No. PCT/EP2025/053232, 2025
